Grant ID RP220470
Awarded On February 16, 2022
Title Overcoming liver toxicity of anti-CD137 cancer immunotherapy
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization The University of Texas Health Science Center at San Antonio
Principal Investigator/Program Director Alexei Tumanov
Cancer Sites All Sites
Contracted Amount $969,471
Lay Summary

Novel antibody-based immunotherapies for cancer are having major clinical impact. However, accompanying immune-mediated adverse reactions, such as liver toxicity, remain the major obstacle of these therapies. Costimulatory molecule called CD137 is a powerful target for immunotherapy. Unfortunately, clinical trials of anti-CD137 antibody (Urelumab) in patients with advanced cancers revealed dramatic liver toxicity. Therefore, overcoming liver toxicity, a major roadblock of anti-CD137 and other checkpoint molecule targeted therapies is crucial.

Our preliminary data identified an immune molecule, called lymphotoxin beta receptor (LTbR) as a critical regulator of anti-CD137 antibody induced hepa...

Read More